drugset / Trial / NCT04046939
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2020-12-03
- Completion
- 2021-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dexpramipexole | Small molecule | 37.5 mg | Oral |
| Comparator | Dexpramipexole | Small molecule | 75 mg | Oral |
| Comparator | Dexpramipexole | Small molecule | 150 mg | Oral |